← Eichor
Study identifier: NCT06543082 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Condition: Acute Coronary Syndrome  ·  Sponsor: CHA University

PhasePhase 4
Planned participants490
Who can joinAll sexes, 20 Years to 90 Years
Healthy volunteersNo

About this study

The previous Mono Antiplatelet and Colchicine Therapy (MACT) pilot study (NCT04949516) demonstrated that it was feasible to discontinue aspirin therapy and administer low-dose colchicine on the day after percutaneous coronary intervention (PCI) in addition to potent P2Y12 inhibitors in patients with acute coronary syndrome (ACS). However, the efficacy and safety of MACT have not yet been investigated. The goal of this clinical trial is to evaluate the clinical outcomes of ticagrelor P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in patients with ACS. The main questions it aims to answer are: * What is the frequency of the composite endpoint of cardiovascular death, nonfatal spontaneous myocardial infarction, nonfatal ischemic stroke, unplanned hospitalization leading to urgent revascularization, and major bleeding at 12 months post-intervention? * What is the frequency of stent thrombosis at 12 months post-intervention? For pre-specified analyses, researchers will compare MACT to less than 1 month, 3-month, and 12-month dual antiplatelet therapy (individual patient data from the T-PASS \[NCT03797651\] and TICO \[NCT02494895\] trials) to determine if MACT is effective in treating ACS. Participants will: * Take low-dose colchicine in addition to ticagrelor maintenance therapy, discontinuing aspirin the day after PCI. * Take a high-sensitivity C-reactive protein (hs-CRP) test 1 month after PCI. * Discontinue colchicine if the hs-CRP level is less …

This description comes directly from the study's public registry record.

Talk to the study team

Hwa-In Kim  ·  82-31-780-5858  ·  niawhz23@gmail.com

Always discuss trial participation with your own doctor first.

Locations (9)

CHA Bundang Medical CenterSeongnam-si, Gyeonggi-do, South KoreaRecruiting
Keimyung University Dongsan HospitalDaegu, South KoreaRecruiting
Wonkwang University HospitalIksan, South KoreaRecruiting
Myongji HospitalIlsan, South KoreaRecruiting
National Health Insurance Service Ilsan HospitalIlsan, South KoreaRecruiting
Seoul National University Bundang HospitalSeongnam, South KoreaRecruiting
Ewha Womans University Seoul HospitalSeoul, South KoreaRecruiting
Gangnam Severance HospitalSeoul, South KoreaRecruiting
Wonju Severance Christian HospitalWŏnju, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06543082